<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Luliconazole: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Luliconazole: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Luliconazole: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="91659" href="/d/html/91659.html" rel="external">see "Luliconazole: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24673740"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Luzu</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F22780327"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antifungal Agent, Topical</li></ul></div>
<div class="block doa drugH1Div" id="F23666071"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="15c0a5bc-b04b-4bce-808a-eba28afcd673">Tinea infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea corporis/tinea cruris:</i>
<b>Topical:</b> Cream: Apply to affected and surrounding area(s) once daily until clinical resolution, typically 1 to 3 weeks (Goldstein 2021; Jones 2014; Kaur 2020; Weinstein 2002; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea pedis (labeled use)/tinea manuum (off-label use):</i>
<b>Topical:</b> Cream: Apply to affected and surrounding area(s) once daily until 1 week after clinical resolution, typically for 2 to 4 weeks total (Draelos 2014; Goldstein 2021; Weinstein 2002; manufacturer’s labeling).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990174"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987529"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F23666072"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F51159501"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="df024980-72ea-4fa0-9c13-db4b25b796e8">Fungal infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fungal infections:</b> Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Tinea pedis or tinea cruris: Children ≥12 years and Adolescents: Refer to adult dosing</p>
<p style="text-indent:-2em;margin-left:4em;">Tinea corporis: Children ≥2 years and Adolescents: Refer to adult dosing</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51344327"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51344328"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F23282778"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Application site reaction, cellulitis, contact dermatitis</p></div>
<div class="block coi drugH1Div" id="F22780330"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F23666063"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">•  Appropriate use: For topical use only; not for oral, ophthalmic, or intravaginal use.</p></div>
<div class="block foc drugH1Div" id="F24673741"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Luzu: 1% (60 g) [contains benzyl alcohol, methylparaben, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (60 g)</p></div>
<div class="block geq drugH1Div" id="F23869284"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F24144990"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Luliconazole External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per gram): $4.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Luzu External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per gram): $9.84</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F23676618"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For topical use only. Not for ophthalmic, oral, or intravaginal use. Apply to affected area and ~1 inch of immediate surrounding area(s). Wash hands following application.</p></div>
<div class="block admp drugH1Div" id="F52614551"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: For topical use only; not for ophthalmic, oral, or intravaginal use. Apply to affected area and ~1 inch of immediate surrounding area(s). Wash hands following application.</p></div>
<div class="block use drugH1Div" id="F22780329"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Fungal infections:</b> Topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by <i>Trichophyton rubrum</i> and <i>Epidermophyton floccosum</i></p></div>
<div class="block off-label drugH1Div" id="F56324185"><span class="drugH1">Use: Off-Label: Adult</span><p>Tinea manuum</p></div>
<div class="block cyt drugH1Div" id="F22813125"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> CYP2C19 (weak)</p></div>
<div class="block dri drugH1Div" id="F22813122"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: CYP2C19 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Weak) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C19 Inhibitors (Weak) may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP2C19 Inhibitors (Weak) may increase the serum concentration of Mavacamten.  Management: Start mavacamten at 5 mg/day if stable on a weak CYP2C19 inhibitor. For those stable on mavacamten who are initiating a weak CYP2C19 inhibitor, reduce mavacamten dose by one dose level.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F23666060"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in some animal reproduction studies. Small amounts of luliconazole are absorbed systemically.</p></div>
<div class="block brc drugH1Div" id="F23666062"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if luliconazole is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block pha drugH1Div" id="F23666065"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Azole antifungal that appears to inhibit ergosterol synthesis by inhibiting the enzyme lanosterol demethylase, resulting in decreased amounts of ergosterol and a corresponding accumulation of lanosterol.</p></div>
<div class="block phk drugH1Div" id="F23666067"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Small amounts may be absorbed following topical application</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99%; to plasma proteins</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23671924"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Lulider</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Lu li te</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">2azole | Afitra l | Bdluli | Brulicon | Clocip l | Defungin | Elnaz | Emluz | Favluz | Fenza l | Ficnx | Fulitra | Fungisure l | Funzi l | Glomycan | Ibilul | Imiderm | L fine | L sys | L topsy | L-trix | Lactfast | Lemed | Lenaz | Lenin | Licozac | Lilituf | Lilu | Llcol | Lofatin | Logifin | Lolicon | Lonizol | Loz fn | Lt mac | Lu fung | Lu gal | Lucaf | Lucazole | Lucee | Lucenza | Ludemold | Ludura | Lugud | Luhon | Luitor | Luizole | Luleze | Lulibet | Lulibor | Lulibrut | Lulibull | Luliclin | Luliclinz | Lulidac | Luliderm | Lulifal | Lulifem | Lulifight | Lulifin | Luligard | Luligee | Luligel | Lulihalt | Luliheal | Lulijen | Lulijon | Lulikil | Lulilok | Lulimac | Luliment | Lulinext | Lulinol | Lulipex | Lulipic | Lulipil | Lulipink | Luliplus | Luliply | Luliporus | Lulirab | Lulirom | Lulirx | Luliskin | Lulisol | Lulisure | Lulitec | Lulitross | Luliz | Luliza | Luly | Lulyera | Lumycan | Lunabet | Lupizol | Luray | Lusaf | Lutriben | Luzibel | Luzo | Lz can | Lzhh | Mycobloc | Myconase | Rosetra L | Syldem | Tinibit l | Ulic | Ulzol | Zocon l | Zyluli</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Lulizol | Lulyera | Tineahit</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Luzu</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lican</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25371767">
<a name="25371767"></a>Draelos ZD, Vlahovic TC, Gold MH, Parish LC, Korotzer A. A randomized, double-blind, vehicle-controlled trial of luliconazole cream 1% in the treatment of interdigital tinea pedis. <i>J Clin Aesthet Dermatol</i>. 2014;7(10):20-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/luliconazole-drug-information/abstract-text/25371767/pubmed" id="25371767" target="_blank">25371767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldstein.1">
<a name="Goldstein.1"></a>Goldstein AO, Goldstein BG. Dermatophyte (tinea) infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 24, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24385117">
<a name="24385117"></a>Jones TM, Jarratt MT, Mendez-Moguel I, et al. A randomized, multicenter, double-blind, vehicle-controlled study evaluating the efficacy and safety of luliconazole cream 1% once daily for 7 days in patients aged ≥ 12 years with tinea cruris. <i>J Drugs Dermatol</i>. 2014;13(1):32-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/luliconazole-drug-information/abstract-text/24385117/pubmed" id="24385117" target="_blank">24385117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33376700">
<a name="33376700"></a>Kaur M, Gupta A, Mahajan R, Gill M. Efficacy, safety, and cost evaluation of the topical luliconazole therapy versus topical clotrimazole therapy in patients with localized dermatophytosis in a tertiary care hospital: an observational study. <i>Int J Appl Basic Med Res</i>. 2020;10(4):260-264. doi:10.4103/ijabmr.IJABMR_207_20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/luliconazole-drug-information/abstract-text/33376700/pubmed" id="33376700" target="_blank">33376700</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Luzu (luliconazole) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12046779">
<a name="12046779"></a>Weinstein A, Berman B. Topical treatment of common superficial tinea infections. <i>Am Fam Physician</i>. 2002;65(10):2095-2102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/luliconazole-drug-information/abstract-text/12046779/pubmed" id="12046779" target="_blank">12046779</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 91589 Version 93.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
